ZION:NASDAQZions Bancorporation N.A. Analysis
Data as of 2026-06-25 - not real-time
$68.30
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Zions Bancorporation (ZION) is trading at $68.30, comfortably above its 20‑day SMA (64.70) and 50‑day SMA (63.04), confirming a bullish price trend. The 200‑day SMA (58.44) further underscores the long‑term upside bias. Momentum remains strong with a bullish MACD histogram (+0.31) and a bullish signal line crossover. However, the RSI 69.4 signals that the stock is approaching overbought territory, and the current price is just shy of the identified resistance at $69.08. Volume has been increasing, supporting the technical strength.
On the fundamentals side, ZION delivers a 10.2% revenue growth and a solid operating margin of 36%, translating to a healthy ROE of 14%. The trailing P/E 10.6 vs industry 16.9 positions the stock as a relative value play. The dividend yield 2.64% with a modest 27% payout ratio suggests sustainable cash returns. The updated fair‑value estimate of $68.75 and a consensus “Buy” rating (median target $68) imply that the market price is essentially fair‑valued with limited upside. Nevertheless, the 30‑day volatility of 21.8% and a beta near 1.0 indicate moderate price swings and sensitivity to broader market moves. Given the blend of growth, attractive yield, and reasonable valuation, the stock is best viewed as a balanced “blend” investment. Overall, the technical momentum, strong earnings profile, and sustainable dividend support a positive outlook, while the modest overbought signal and near‑term resistance suggest a cautious short‑term stance.
On the fundamentals side, ZION delivers a 10.2% revenue growth and a solid operating margin of 36%, translating to a healthy ROE of 14%. The trailing P/E 10.6 vs industry 16.9 positions the stock as a relative value play. The dividend yield 2.64% with a modest 27% payout ratio suggests sustainable cash returns. The updated fair‑value estimate of $68.75 and a consensus “Buy” rating (median target $68) imply that the market price is essentially fair‑valued with limited upside. Nevertheless, the 30‑day volatility of 21.8% and a beta near 1.0 indicate moderate price swings and sensitivity to broader market moves. Given the blend of growth, attractive yield, and reasonable valuation, the stock is best viewed as a balanced “blend” investment. Overall, the technical momentum, strong earnings profile, and sustainable dividend support a positive outlook, while the modest overbought signal and near‑term resistance suggest a cautious short‑term stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near resistance at $69.08
- RSI indicating overbought conditions
- increasing volume supporting momentum
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- 10% revenue growth and strong operating margins
- P/E well below industry average
- sustainable dividend yield 2.64%
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- solid ROE of 14% and net cash position
- fair valuation with limited downside risk
- consistent dividend policy with low payout ratio
Key Metrics & Analysis
Financial Health
Revenue Growth10.20%
Profit Margin28.36%
P/E Ratio10.6
ROE14.12%
ROA1.09%
P/B Ratio1.4
Op. Cash Flow$1.3B
Industry P/E16.9
Technical Analysis
TrendBullish
RSI69.4
Support$60.61
Resistance$69.08
MA 20$64.70
MA 50$63.04
MA 200$58.44
MACDBullish
VolumeIncreasing
Fear & Greed Index88.16
Valuation
Fair Value$133.49
Target Price$69.24
Upside/Downside1.37%
GradeFair
TypeBlend
Dividend Yield2.64%
Risk Assessment
Beta1.04
Volatility21.78%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.